Hormonal receptors in lung adenocarcinoma: expression and difference in outcome by sex.
BACKGROUND
Lung cancer seems to have different epidemiological, biomolecular and clinical characteristics in females than in males, with a better prognosis for women. The aim of the study is to determine gender differences in lung adenocarcinoma in terms of androgen (AR), estrogen (ER)α and progesterone (PgR) receptors expression and their impact on outcome.


RESULTS
Overall survival was significantly better in ERα and in PgR positive lung adenocarcinoma patients (median survival 45 vs. 19 months).Eight out of 62 patients showed positive expression of nuclear (n) AR and 18 of cytoplasmic (c) AR with a significantly better survival (49 vs. 19 and 45 vs. 19 months, respectively). There was a significant difference in survival between patients with vs. without c-AR expression (30 vs. 17 months). Finally, in the subgroup of women, median survival was greater in positive expression of c-AR than for women with negative c-AR (45 vs. 21 months).


METHODS
We conducted an analysis on a cohort of 62 patients with advanced NSCLC treated at our institution. We investigated the immunohistochemical expression of n/c AR, ERα and PgR in 62 NSCLC and we correlated it with patients' clinic-pathologic characteristics and with prognosis.


CONCLUSIONS
Our results showed that the positive expression of one hormonal receptor could represent a prognostic factor.Furthermore our study suggests that AR should become object of close examination in a larger series of lung adenocarcinoma patients, also for selection of the patients with best prognosis that can perform more chemotherapy lines.
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Rossana
R
Berardi
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Francesca
F
Morgese
Section of Pathological Anatomy and Histopathology, Deparment of Neuroscience, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Alfredo
A
Santinelli
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Azzurra
A
Onofri
Section of Pathological Anatomy and Histopathology, Deparment of Neuroscience, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Tommasina
T
Biscotti
Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.
Alessandro
A
Brunelli
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Miriam
M
Caramanti
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Agnese
A
Savini
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Mariagrazia
M
De Lisa
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Zelmira
Z
Ballatore
Department of Thoracic Surgery, St. James's University Hospital, Leeds, UK.
Cecilia
C
Pompili
Thoracic Surgery, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Michele
M
Salati
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Paola
P
Mazzanti
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.
Mariangela
M
Torniai
Medical Oncology Unit, Università Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti di Ancona, Ancona, Italy.|Actual Position: Oncologia Medica-Università degli studi di Modena e Reggio Emilia Modena, Italy.
Stefano
S
Cascinu
D000230:Adenocarcinoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000077192:Adenocarcinoma of Lung; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis*; D002289:Carcinoma, Non-Small-Cell Lung / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D002467:Cell Nucleus / Q000737:chemistry; D003600:Cytosol / Q000737:chemistry; D018572:Disease-Free Survival; D047628:Estrogen Receptor alpha / Q000032:analysis*; D005260:Female; D054624:Health Status Disparities; D006801:Humans; D007150:Immunohistochemistry; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011944:Receptors, Androgen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*; D012737:Sex Factors; D013997:Time Factors; D016896:Treatment Outcome
C410798:AR protein, human; D014408:Biomarkers, Tumor; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha; D011944:Receptors, Androgen; D011980:Receptors, Progesterone
androgen receptor; estrogen receptor; gender differences; non-small cell lung cancer; progesterone receptor
Ann Thorac Surg. 2011 May;91(5):1562-7
21524465
Fertil Steril. 2002 Apr;77 Suppl 4:S3-5
12007895
Carcinogenesis. 2010 Oct;31(10):1778-86
20729390
Arch Pathol Lab Med. 2000 Oct;124(10):1467-70
11035577
PLoS One. 2010 Mar 09;5(3):e9584
20231893
J Thorac Dis. 2015 Sep;7(9):1588-94
26543606
J Natl Cancer Inst. 2000 Jan 5;92(1):24-33
10620630
Clin Lung Cancer. 2012 Nov;13(6):416-23
22658344
Zhongguo Fei Ai Za Zhi. 2008 Feb 20;11(1):126-9
20727281
Clin Cancer Res. 2005 Jul 15;11(14):5084-9
16033821
Clin Cancer Res. 2009 Sep 1;15(17):5359-68
19706809
World J Surg Oncol. 2012 Jul 11;10:141
22784503
Cancer Res. 2005 Jul 15;65(14):6450-8
16024650
J Thorac Oncol. 2010 Jan;5(1):17-22
19875972
Clin Cancer Res. 2011 Jan 1;17(1):154-64
21062926
Int J Cancer. 2013 Jun 1;132(11):2630-9
23129166
Eur J Cancer. 2009 Jan;45(2):248-60
19095437
Mol Cell Endocrinol. 2002 Feb 25;188(1-2):125-40
11911952
Cancer Epidemiol Biomarkers Prev. 1998 Sep;7(9):735-48
9752981
Anticancer Res. 1996 Nov-Dec;16(6B):3803-6
9042261
Cancer. 2003 Mar 1;97(5):1263-70
12599234
JAMA. 2004 Apr 14;291(14):1763-8
15082704
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
21296855
J Clin Oncol. 2007 Feb 10;25(5):561-70
17290066
Chest. 1997 May;111(5):1414-6
9149602
Cancer. 2012 Jan 1;118(1):157-63
21713768
J Clin Oncol. 2009 Jan 20;27(3):411-7
19064969